These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 3533565

  • 1. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
    Brøsen K, Klysner R, Gram LF, Otton SV, Bech P, Bertilsson L.
    Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
    [Abstract] [Full Text] [Related]

  • 2. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin.
    Brøsen K, Gram LF, Kragh-Sørensen P.
    Ther Drug Monit; 1991 Mar; 13(2):177-82. PubMed ID: 2053127
    [Abstract] [Full Text] [Related]

  • 3. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine.
    Brøsen K, Gram LF.
    Eur J Clin Pharmacol; 1989 Mar; 37(2):155-60. PubMed ID: 2792169
    [Abstract] [Full Text] [Related]

  • 4. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype.
    Brøsen K, Otton SV, Gram LF.
    Clin Pharmacol Ther; 1986 Nov; 40(5):543-9. PubMed ID: 3769385
    [Abstract] [Full Text] [Related]

  • 5. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.
    Brøsen K, Gram LF.
    Clin Pharmacol Ther; 1988 Apr; 43(4):400-6. PubMed ID: 3356084
    [Abstract] [Full Text] [Related]

  • 6. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
    Bertilsson L, Dengler HJ, Eichelbaum M, Schulz HU.
    Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
    [Abstract] [Full Text] [Related]

  • 7. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
    Dayer P, Kronbach T, Eichelbaum M, Meyer UA.
    Biochem Pharmacol; 1987 Dec 01; 36(23):4145-52. PubMed ID: 3689440
    [Abstract] [Full Text] [Related]

  • 8. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine.
    Brøsen K, Zeugin T, Meyer UA.
    Clin Pharmacol Ther; 1991 Jun 01; 49(6):609-17. PubMed ID: 2060250
    [Abstract] [Full Text] [Related]

  • 9. Simultaneous high-performance liquid chromatography-electrochemical detection determination of imipramine, desipramine, their 2-hydroxylated metabolites, and imipramine N-oxide in human plasma and urine: preliminary application to oxidation pharmacogenetics.
    Koyama E, Kikuchi Y, Echizen H, Chiba K, Ishizaki T.
    Ther Drug Monit; 1993 Jun 01; 15(3):224-35. PubMed ID: 8333003
    [Abstract] [Full Text] [Related]

  • 10. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.
    Eichelbaum M, Bertilsson L, Säwe J.
    Br J Clin Pharmacol; 1983 Mar 01; 15(3):317-21. PubMed ID: 6849767
    [Abstract] [Full Text] [Related]

  • 11. Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group.
    Nielsen KK, Brøsen K, Gram LF.
    Eur J Clin Pharmacol; 1992 Mar 01; 43(4):405-11. PubMed ID: 1451721
    [Abstract] [Full Text] [Related]

  • 12. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.
    Skjelbo E, Brøsen K, Hallas J, Gram LF.
    Clin Pharmacol Ther; 1991 Jan 01; 49(1):18-23. PubMed ID: 1988236
    [Abstract] [Full Text] [Related]

  • 13. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study.
    Skjelbo E, Gram LF, Brøsen K.
    Br J Clin Pharmacol; 1993 Mar 01; 35(3):331-4. PubMed ID: 8471415
    [Abstract] [Full Text] [Related]

  • 14. Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.
    Dayer P, Leemann T, Küpfer A, Kronbach T, Meyer UA.
    Eur J Clin Pharmacol; 1986 Mar 01; 31(3):313-8. PubMed ID: 2878813
    [Abstract] [Full Text] [Related]

  • 15. Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.
    Gut J, Catin T, Dayer P, Kronbach T, Zanger U, Meyer UA.
    J Biol Chem; 1986 Sep 05; 261(25):11734-43. PubMed ID: 3745165
    [Abstract] [Full Text] [Related]

  • 16. The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms.
    Meyer UA, Skoda RC, Zanger UM.
    Pharmacol Ther; 1990 Sep 05; 46(2):297-308. PubMed ID: 2181495
    [Abstract] [Full Text] [Related]

  • 17. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.
    Eichelbaum M, Bertilsson L, Säwe J, Zekorn C.
    Clin Pharmacol Ther; 1982 Feb 05; 31(2):184-6. PubMed ID: 7056024
    [Abstract] [Full Text] [Related]

  • 18. Nonlinear kinetics of imipramine in low and medium plasma level ranges.
    Sindrup SH, Brøsen K, Gram LF.
    Ther Drug Monit; 1990 Sep 05; 12(5):445-9. PubMed ID: 2293406
    [Abstract] [Full Text] [Related]

  • 19. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.
    Evans DA, Harmer D, Downham DY, Whibley EJ, Idle JR, Ritchie J, Smith RL.
    J Med Genet; 1983 Oct 05; 20(5):321-9. PubMed ID: 6644761
    [Abstract] [Full Text] [Related]

  • 20. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
    Madsen H, Nielsen KK, Brøsen K.
    Br J Clin Pharmacol; 1995 Apr 05; 39(4):433-9. PubMed ID: 7640151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.